HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans.

Abstract
The objective of the present study was to evaluate the effects of EMD 61753 (asimadoline), a kappa-opioid receptor agonist with restricted access to the central nervous system, on postoperative pain in patients who underwent knee surgery and on nociceptive thresholds and inflammation in rats treated with Freund's complete adjuvant. Patients treated with EMD 61753 (10 mg p.o.) tended to report an increase in pain, as evaluated by a visual analog scale and by the time to the first request for and the total amount of supplemental analgesic medication. The global tolerability of EMD 61753 was assessed as significantly inferior to that of a placebo by the investigator. In rats, the bilateral intraplantar (i.pl.) injection of EMD 61753 (0.1-3.2 mg) resulted in dose-dependent antinociception in both inflamed and noninflamed paws, with a peak at 5 min after injection, as evaluated by the paw pressure method. However, at later time points (1 h-4 days), a significant decrease in the paw pressure threshold was observed, confirming its tendency toward a hyperalgesic action in humans. This was accompanied by an increase in paw volume and paw temperature, with a peak at 6 h after injection. EMD 61753 (1.6 mg)-induced analgesia was blocked by the peripheral opioid receptor antagonist naloxone methiodide (2.5-10 mg/kg s.c.) and by the kappa receptor antagonist nor-binaltorphimine (0.1 mg; i.pl.). In contrast, EMD 61753 (1.6 mg)-induced hyperalgesia and increases in paw volume and paw temperature were blocked neither by naloxone methiodide (10-40 mg/kg s.c.) nor by dizocilpine maleate (0.003-0.009 mg i.pl.), a N-methyl-D-aspartic acid receptor antagonist. These data show differentially mediated peripheral actions of EMD 61753: kappa-opioid receptor-induced analgesia and nonopioid, non-N-methyl-D-aspartic acid hyperalgesic and proinflammatory effects.
AuthorsH Machelska, M Pflüger, W Weber, M Piranvisseh-Völk, J D Daubert, R Dehaven, C Stein
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 290 Issue 1 Pg. 354-61 (Jul 1999) ISSN: 0022-3565 [Print] United States
PMID10381799 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Acetamides
  • Analgesics, Opioid
  • Pyrrolidines
  • Receptors, Opioid, kappa
  • asimadoline
Topics
  • Acetamides (metabolism, pharmacology, therapeutic use)
  • Adult
  • Analgesics, Opioid (metabolism, pharmacology, therapeutic use)
  • Animals
  • Arthritis, Experimental (drug therapy, pathology, physiopathology)
  • Arthroscopy
  • Behavior, Animal (drug effects)
  • CHO Cells
  • Cricetinae
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation (drug therapy, pathology, physiopathology)
  • Knee Joint (surgery)
  • Male
  • Pain (drug therapy, physiopathology)
  • Pain Measurement
  • Pain Threshold (drug effects)
  • Pain, Postoperative (drug therapy, physiopathology)
  • Pyrrolidines (metabolism, pharmacology, therapeutic use)
  • Rats
  • Rats, Wistar
  • Receptors, Opioid, kappa (agonists, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: